SUTRO BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
SUTRO BIOPHARMA, INC. (STRO) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -2.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-03-23
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2025 was -2.20%.
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -5.80%.
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -3.10%.
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was -7.90%, a 313.51% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -2.20% 10-K · filed 2026-03-23 | |
| 2024-12-31 | -5.80% 10-K · filed 2026-03-23 | |
| 2023-12-31 | -3.10% 10-K · filed 2025-03-13 | -0.70% 10-K · filed 2024-03-25 |
| 2022-12-31 | -7.90% 10-K · filed 2025-03-13 | 5.10% 10-K · filed 2023-03-30 |
| 2021-12-31 | 3.70% 10-K · filed 2024-03-25 | |
| 2020-12-31 | 9.30% 10-K · filed 2023-03-30 | |
| 2019-12-31 | 4.90% 10-K · filed 2022-02-28 | |
| 2018-12-31 | 7.50% 10-K · filed 2021-03-18 | |
| 2017-12-31 | 3.80% 10-K · filed 2020-03-16 | |
| 2016-12-31 | -21.60% 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |